ADALIMUMAB

Brand name:

• Humira®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Moderate to severe hidradenitis suppurativa

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (Minor)

Comment:

--

Submission sponsor:

AbbVie Pty Ltd

Other PBAC consideration:

--

Submission received for:

November 2019 PBAC meeting

Opportunity for consumer comment:

Open 28/08/2019 and close 09/10/2019 (see PBS Website)

PBAC meeting:

Held on 06/11/2019

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

01/09/2020

Lodgement of required documentation:

16/09/2020

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 09/10/2020

Status:

Finalised

Government processes:

Commenced on 01/02/2021

Medicine listed on the PBS:

01/04/2021 (see PBS schedule)

---